Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review

The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially...

Descripción completa

Detalles Bibliográficos
Autores: de la Rosa-Carrillo, D., Suárez-Cuartín, G., Sibila, O., Golpe Gómez, Rafael, Girón, R.-M., Martínez-García, M.-Á.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21422
Acceso en línea:https://portalcientifico.sergas.gal//documentos/64995bb771c692789f1e07bc
http://hdl.handle.net/20.500.11940/21422
Access Level:acceso abierto
Palabra clave:AS Lugo
CHULA
id ES_7d54428a78c61dacbe2f1b648d64ea55
oai_identifier_str oai:runa.sergas.gal:20.500.11940/21422
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and Safety of Dry Powder Antibiotics: A Narrative Reviewde la Rosa-Carrillo, D.Suárez-Cuartín, G.Sibila, O.Golpe Gómez, RafaelGirón, R.-M.Martínez-García, M.-Á.AS LugoCHULAThe use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.2023info:eu-repo/semantics/articlehttps://portalcientifico.sergas.gal//documentos/64995bb771c692789f1e07bchttp://hdl.handle.net/20.500.11940/21422reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/214222026-06-12T08:40:47Z
dc.title.none.fl_str_mv Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
title Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
spellingShingle Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
de la Rosa-Carrillo, D.
AS Lugo
CHULA
title_short Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
title_full Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
title_fullStr Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
title_full_unstemmed Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
title_sort Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review
dc.creator.none.fl_str_mv de la Rosa-Carrillo, D.
Suárez-Cuartín, G.
Sibila, O.
Golpe Gómez, Rafael
Girón, R.-M.
Martínez-García, M.-Á.
author de la Rosa-Carrillo, D.
author_facet de la Rosa-Carrillo, D.
Suárez-Cuartín, G.
Sibila, O.
Golpe Gómez, Rafael
Girón, R.-M.
Martínez-García, M.-Á.
author_role author
author2 Suárez-Cuartín, G.
Sibila, O.
Golpe Gómez, Rafael
Girón, R.-M.
Martínez-García, M.-Á.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv AS Lugo
CHULA
topic AS Lugo
CHULA
description The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://portalcientifico.sergas.gal//documentos/64995bb771c692789f1e07bc
http://hdl.handle.net/20.500.11940/21422
url https://portalcientifico.sergas.gal//documentos/64995bb771c692789f1e07bc
http://hdl.handle.net/20.500.11940/21422
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411655651164160
score 15.81155

Similares en LA Referencia